Samsung Electronics Posts Record Q4 2025 Profit as AI Chip Demand Soars 
SpaceX Updates Starlink Privacy Policy to Allow AI Training as xAI Merger Talks and IPO Loom 
CSPC Pharma and AstraZeneca Forge Multibillion-Dollar Partnership to Develop Long-Acting Peptide Drugs 
Apple Faces Margin Pressure as Memory Chip Prices Surge Amid AI Boom 
Trump Threatens Aircraft Tariffs as U.S.-Canada Jet Certification Dispute Escalates 
Microsoft AI Spending Surge Sparks Investor Jitters Despite Solid Azure Growth 
Chinalco and Rio Tinto Acquire Controlling Stake in Brazil’s CBA for $903 Million 
Apple Forecasts Strong Revenue Growth as iPhone Demand Surges in China and India 
Bob Iger Plans Early Exit as Disney Board Prepares CEO Succession Vote 
Elon Musk’s SpaceX Explores Merger Options With Tesla or xAI, Reports Say 
NVIDIA, Microsoft, and Amazon Eye Massive OpenAI Investment Amid $100B Funding Push 
Climate Adaptation at Home: How Irrigreen Makes Conservation Effortless 
Amazon Stock Dips as Reports Link Company to Potential $50B OpenAI Investment 
Pentagon and Anthropic Clash Over AI Safeguards in National Security Use 
Panama Supreme Court Voids Hong Kong Firm’s Panama Canal Port Contracts Over Constitutional Violations 
Saks Global to End Saks on Amazon Partnership Amid Bankruptcy Restructuring 
NEW YORK, May 25, 2017 -- Blake Insomnia Therapeutics Inc. (OTCQB:BKIT) a New York based pharmaceutical company is pleased to announce the appointment of Kyle Sarwal and Ajit Johal to its Board of Directors.
Mr. Sarwal is a director and business development expert for SAJO Consulting, a company with management, research, scientific, and regulatory expertise. Mr. Sarwal has over 20 years’ experience in acquiring and growing companies, managing technology and information systems, managing teams and businesses, advisory and strategic planning.
Mr. Johal is a director and clinical subject matter expert for SAJO Consulting LLC. He is also the CEO of Next Level Medication Management INC, a Canadian based company dedicated to healthcare innovation and sustainability.
Mr. Johal is a graduate from the Leslie Dan Faculty of Pharmacy at the University of Toronto. He holds a Board Certification in Psychiatric Pharmacy, awarded by the Board of Pharmacy Specialties in the United States. He is a clinical instructor at UBC’s Faculty of Pharmaceutical Sciences and has worked as lead clinical pharmacist for a number of outreach programs including the Integrated Medication Management Program and the Coast Mental Health Medication Program.
“Ajit brings to Blake Insomnia Therapeutics a valued combination of pharmaceutical expertise with academic experience,” said Birger Jan Olsen, President and CEO of Blake Insomnia Therapeutics. “His experience in psychiatric pharmacotherapy brings tremendous value to the development of Blake Insomnia’s portfolio of novel and innovative pharmaceutical products.” Both Mr. Sarwal and Mr. Ajit will start working on the board as soon as the Company has obtained Director’s and Officer’s Insurance.
Sajo Consulting LLC
Sajo designs solutions and strategies in getting products to market faster and smarter. Their research, scientific, regulatory and operational team puts best practice standards to work while building innovative solutions for constantly evolving industries.
Blake Insomnia Therapeutics Inc.
Blake is a New York-based pharmaceutical company devoted to improving night-time and daytime quality of life for people with insomnia. The company’s patent-pending ZLX-1 compound has demonstrated efficacy without producing the side effects identified as the No. 1 problem with current sleep medication. The ZLX-1 compound is marketed under the brand name, Zleepax™.
Please visit www.blakeinsomnia.com to learn more about the company, management and the ZLX-1 compound.
Contact Birger Jan Olsen CEO Blake Insomnia Therapeutics Inc. 1 (888) 612-2905 [email protected]
